Regeneron Pharmaceuticals, Inc. cash flow to debt ratio of 184.00% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Regeneron Pharmaceuticals, Inc.'s free cash flow has increased 11.35% from $3.66B last year to $4.08B, signaling increasing performance

Regeneron Pharmaceuticals, Inc.'s debt to equity ratio is 0.06, which means that the company's assets are healthy financed, signaling financial stability.

Regeneron Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 0.09 last year to 0.06 today, signaling strengthened financials

Regeneron Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.

Regeneron Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Regeneron Pharmaceuticals, Inc.'s profit margin has decreased (10.32%) in the last year from 31.07% to 27.86%, signaling decreasing performance

Regeneron Pharmaceuticals, Inc.'s short-term assets of $18.02B exceed its short-term liabilities of $4.37B

Regeneron Pharmaceuticals, Inc.'s return on assets of 10.37% is higher than the 5.00% threshold, indicating efficient asset utilization

Regeneron Pharmaceuticals, Inc.'s return on equity of 13.81%, is lower than 15.00%, indicating bad performance

Regeneron Pharmaceuticals, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Regeneron Pharmaceuticals, Inc. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Regeneron Pharmaceuticals, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Regeneron Pharmaceuticals, Inc. has a free cash flow yield of 4.90%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Regeneron Pharmaceuticals, Inc.'s yearly earnings has increased 2.09% since last year from $4.41B to $4.50B, signaling increasing performance

Regeneron Pharmaceuticals, Inc.'s yearly revenue has increased 0.99% since last year from $14.20B to $14.34B, signaling increasing performance

ROIC 9.19% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Regeneron Pharmaceuticals, Inc.'s 3-year revenue CAGR of 5.62% is positive, indicating growing revenue over the past 3 years

Regeneron Pharmaceuticals, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Regeneron Pharmaceuticals, Inc. had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Regeneron Pharmaceuticals, Inc. is overvalued relative to its fair value price of 701.06 based on Discounted Cash Flow model

Regeneron Pharmaceuticals, Inc. has an earnings yield of 5.18%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Regeneron Pharmaceuticals, Inc. is overvalued relative to its fair value price of 395.95 based on EBITDA multiple model

Regeneron Pharmaceuticals, Inc. has an EV/EBITDA ratio of 13.29x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Regeneron Pharmaceuticals, Inc. is undervalued relative to its fair value price of 969.05 based on Earnings Fair Value model

Regeneron Pharmaceuticals, Inc. has a PEG-ratio over 1 which is considered overvalued

Regeneron Pharmaceuticals, Inc. has a price-to-book ratio of 2.63x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Regeneron Pharmaceuticals, Inc. has a price-to-sales ratio of 5.38x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue